ArticleBlood2017
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 147 citations in OpenAlex.
- Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.Blood · 2021Trial
- Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.Journal of translational medicine · 2019Trial
- Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL-Fusion Leukemia.Cancer science · 2026Article
- The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation.The Journal of biological chemistry · 2026Article
- Postbiotics Combination Synergises the Antiproliferative Effects of Doxorubicin in Gastric Cancer Cells: A Cellular and Molecular Deep Dive.International journal of molecular sciences · 2025Article
- Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity.British journal of haematology · 2025Article
- KDM4A-driven SMAD5/TGFβ axis activation as a therapeutic target in cholangiocarcinoma: mechanistic insights and translational implications.Cell & bioscience · 2025Article
- SETD2 suppresses tumorigenesis in a KRASeLife · 2025Article
- Identification of novel genetic mutations for the treatment prognostication of canine lymphoma.NPJ precision oncology · 2025Article
- Integrated Computational and Functional Screening Identifies G9a Inhibitors for SETD2-mutant Leukemia.Genomics, proteomics & bioinformatics · 2025Article
- Impact of Tyrosine Kinase Inhibitors on the Expression Pattern of Epigenetic Regulators.Cancers · 2025Article
- SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.Clinical and translational medicine · 2025Article
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
- Catalytic activity of Setd2 is essential for embryonic development in mice: establishment of a mouse model harboring patient-derived Setd2 mutation.Frontiers of medicine · 2024Article
- REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.Leukemia · 2024Article
- KDM4A promotes malignant progression of breast cancer by down-regulating BMP9 inducing consequent enhancement of glutamine metabolism.Cancer cell international · 2024Article
- SETD2 in cancer: functions, molecular mechanisms, and therapeutic regimens.Cancer biology & medicine · 2024Article
- A multiomic characterization of the leukemia cell line REH using short- and long-read sequencing.Life science alliance · 2024Article
- KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells.Antiviral research · 2024Article
- The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities.Genes & diseases · 2024Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 2 countries.
Brenton G MarDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
S Haihua ChuDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Josephine D KahnDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Andrei V KrivtsovDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY; and.
Cecilia A CastellanoDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Jacob L KotlierDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Rebecca L ZonDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Marie E McConkeyDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Jonathan ChabonDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Ryan ChappellDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Peter V GraumanDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
James J HsiehOncology Division, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO.
Scott A ArmstrongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Benjamin L EbertDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USMemorial Sloan Kettering Cancer Center · USWashington University in St. Louis · US
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI DANIEL J DEANGELO · 1996 to 2026
$52.5MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MChemotherapy resistance induced by SETD2 loss in leukemiaK08CA184419 · NCI · DANA-FARBER CANCER INST · PI MAR, BRENTON G · 2016 to 2017
$354kHoward Hughes Medical InstituteNCI NIH HHS K08 CA184419NCI NIH HHS P01 CA066996NHLBI NIH HHS R01 HL082945
Abstract
Mutations in
Indexed as
DNA DamageAminopyridinesAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalCytarabineDrug Resistance, NeoplasmHEK293 CellsHistone-Lysine N-MethyltransferaseHistonesHumansHydrazonesLeukemia, ExperimentalLysineMethylationAminopyridinesAntineoplastic AgentsCytarabineHistone-Lysine N-MethyltransferaseHistonesHydrazonesJIB-04LysineSETD2 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.